The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Heart transplants are complex, costly, and risky—but for patients with heart failure, they are often the only option for ...

Infection-related hospitalization (IRH) is associated with incident heart failure, heart failure with preserved ejection ...

New research explores how point-of-care lung ultrasound can improve prehospital identification of acute heart failure ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

WhiteSwell has reported encouraging results from its DELTA-HF trial, which evaluated the minimally invasive catheter-based ...

Recent reports reveal heart disease is the leading cause of death in the U.S., many of whom are younger than 45. Here's what ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

Using the BiovitalsHF software to personalize recommendations got more patients on all four pillars of therapy.

The doctor became a patient after ignoring his own heart attack symptoms. He's urging others not to make the same mistake.